Product Image

Herbal Extract Memory Complex

Swanson Ultra
4.6
★ ★ ★ ★ ★
(914 ratings)
Vinpocetine 15 mg
Ginkgo
Product Image
Score82
A strong-value, three-pathway memory blend whose ginkgo and Huperzia standardization remain incomplete.
How scoring works
Quantity:60 Capsule(s) • (60 servings)
Goals:
Cognitive Support
Productivity Boost
Brain Health
Mental Focus

Score 82

A strong-value, three-pathway memory blend whose ginkgo and Huperzia standardization remain incomplete.
How scoring works
$15.09($0.25 per serving)
iHerb
$ 15.09
iHerb
$ 15.09
Amazon
$ 16.09
Walmart
$ 15.49
Report prices

Analysis

Ginkgo reaches a useful daily amount and vinpocetine sits in a well-aligned range for the formula. Together they emphasize cerebral circulation, while Huperzia adds a separate acetylcholine-related pathway.

The Huperzia extract amount is shown, but its huperzine A content is not. Ginkgo similarly lists active-marker classes without percentages, so two of the three ingredients lack the details needed to judge active potency.

One capsule and a low serving cost make the blend convenient. It suits experienced nootropic users better than people taking blood thinners, cholinergic medicines, or multiple cognitive supplements.

Who is it for
  • Adults seeking a compact memory-support formula
  • Experienced users who can screen medication interactions
Best for
  • Memory and mental focus
  • One-capsule cognitive routines
  • Budget-conscious nootropic use

Pros

  • Useful ginkgo amount
  • Clearly disclosed vinpocetine
  • Adds Huperzia
  • One-capsule serving
  • Low cost

Cons

  • No ginkgo marker percentages
  • Huperzine A yield is unknown
  • Inactive-ingredient quality is not supplied

Warnings

  • Ginkgo and vinpocetine may add to anticoagulant or antiplatelet effects, increasing bruising or bleeding risk.
  • Vinpocetine should not be used during pregnancy or when pregnancy is possible.
  • Huperzia may cause nausea, dizziness, vivid dreams, or a slow heart rate if its huperzine content is meaningful.
  • Do not combine Huperzia casually with acetylcholinesterase inhibitors such as donepezil or rivastigmine because cholinergic effects may add together.

Nutrient quality

82 Highest impact

Ginkgo marker classes are named, but their percentages and huperzine yield are not supplied. Ginkgo and vinpocetine reach useful amounts, while the active yield from Huperzia remains unknown, and the three ingredients cover circulation and cholinergic pathways relevant to memory support.

.

Ingredient transparency

82 Highest impact

Every listed active has a specific amount and no proprietary blend obscures the formula. Complete intake directions and inactive ingredients are not supplied, leaving part of the label unverified.

.

Customer satisfaction

71 High impact

The supplied aggregate satisfaction level is strong. The large feedback volume provides a dependable aggregate.

.

Value for money

92 Highest impact

The formula quality is strong for its low cost despite incomplete botanical standardization. A complete serving provides unusually good value for three cognitive actives, and the product compares favorably with similar multi-ingredient memory formulas.

.
Report analysis

Goals

Cognitive Support
Cognitive Support
Impact
High effect
B+ Goal FitC+ Strength of SupportC+ CoverageA- Formula Quality

Ginkgo, vinpocetine, and Huperzia serrata create a focused circulation and cholinergic memory formula. The ginkgo amount reaches a commonly used daily level.

Ginkgo marker percentages and the active Huperzine A yield are not supplied, limiting dose confidence. Ginkgo may increase bleeding risk for users taking anticoagulant or antiplatelet medicines.

Study evidence
Ginkgo Supportive 87 studies
Productivity Boost
Productivity Boost
Impact
High effect
B Goal FitC+ Strength of SupportC- CoverageA Formula Quality
Vinpocetine · 15 mg

Ginkgo, vinpocetine, and club moss create a focused circulation and cholinergic memory formula. Human evidence for routine productivity is moderate, and active standardization is missing for both botanicals.

Ginkgo and vinpocetine reach useful weights, while the active Huperzine A yield from club moss is not stated. Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.

Study evidence
Ginkgo Supportive 20 studies
Ginkgo Supportive 12 studies
Brain Health
Brain Health
Impact
High effect
B- Goal FitC+ Strength of SupportB- CoverageB+ Formula Quality

Ginkgo, vinpocetine, and Huperzia serrata combine circulation and acetylcholine-related support. The vinpocetine and ginkgo amounts are useful, but huperzine content and ginkgo standardization are not stated.

The blend covers more than one cognitive pathway while remaining compact. Vinpocetine is unsuitable during pregnancy, and ginkgo can raise bleeding risk with anticoagulant or antiplatelet medicines.

Study evidence
Ginkgo Supportive 90 studies
Vinpocetine Supportive 7 studies
Mental Focus
Mental Focus
Impact
High effect
B Goal FitB- Strength of SupportC CoverageB+ Formula Quality

Ginkgo, vinpocetine, and huperzia combine cerebral-circulation and cholinergic mechanisms relevant to memory and focus. The ginkgo and vinpocetine amounts are plausible, but the huperzine A yield from 7.5 mg of huperzia extract is not stated.

The blend offers two distinct cognitive pathways with reasonable depth, although it lacks an alertness or stress-resilience component. Ginkgo and vinpocetine may increase bleeding or lower blood pressure, while huperzia can intensify cholinergic medicines and cause nausea or a slow heartbeat.

Study evidence
Ginkgo Supportive 28 studies
Vinpocetine Supportive 3 studies
Vision Support
Vision Support
Impact
Moderate effect
D Goal FitB Strength of SupportD CoverageC+ Formula Quality

Ginkgo and vinpocetine may support ocular circulation, but the formula is designed mainly for memory. Huperzia adds no clearly disclosed vision-relevant active amount.

The ginkgo and vinpocetine amounts are practical for their intended circulation roles. Missing ginkgo standardization percentages and huperzine content make the full potency uncertain.

Study evidence
Ginkgo Supportive 11 studies
Vinpocetine Supportive 1 study

Ingredients

IngredientAmount per serving
Ginkgo biloba leaf extract (Flavone Glycosides, Terpene Lactones)
 120 mg
Vinpocetine
15 mg
Huperzia serrata extract
7.5 mg
Adults 18–50
Report overview
Vinpocetine · 15 mg OverallScore92
A- Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyA Value

The 15 mg vinpocetine dose is clearly disclosed and sits comfortably within the usual target range. Ginkgo and Huperzia serrata add complementary ingredients, though the active huperzine content is not stated. One capsule provides the complete serving at a competitive cost, while inactive-ingredient quality remains unverified.

View ingredientView products
Ginkgo (Flavone Glycosides, Terpene Lactones) · 120 mg OverallScore48
F Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyF Value

The extract names both major active-marker classes but does not disclose their percentages or a purity standard. The fully disclosed daily amount aligns with the preferred clinical range. Low cost appears attractive, but incomplete standardization prevents a reliable value comparison.

View ingredientView products
Loading alternative details
79 Performance

Ginkgo with Vinpocetine

Swanson Superior Herbs
<p>For a stronger fit within the relevant ingredient pathway, ginkgo and vinpocetine form a concise circulation-focused cognitive blend at practical amounts. It does not replace the original Huperzia pathway; missing ginkgo standardization limits confidence in extract quality.</p>
84 Performance

Ginkgo Biloba 120 mg

California Gold Nutrition EuroHerbs
<p>For a stronger fit within the relevant ingredient pathway, the extract amount fits common daily use and names both key marker groups. It does not replace vinpocetine and the original Huperzia pathway; missing marker percentages and a purity guarantee are the main limitations, while the supply delivers strong value.</p>
84 Performance

Ginkgo Biloba Phytosome 60 mg

Natural Factors HerbalFactors
<p>For a stronger fit within the relevant ingredient pathway, a recognized phytosome extract provides strong quality and absorption support. It does not replace vinpocetine and the original Huperzia pathway; ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.</p>
83 Budget

Ginkgo Biloba 60 mg

NOW
<p>At a lower serving cost than the original, the formula combines a maintenance extract with additional ginkgo leaf powder and names both key marker groups. It does not replace vinpocetine and the original Huperzia pathway; missing marker percentages limit standardization confidence, but the very long supply provides excellent value.</p>
83 Budget

Ginkgo Biloba 60 mg

Swanson Superior Herbs
<p>At a lower serving cost than the original, a recognized GinkgoSelect extract provides strong standardization and purity assurance. It does not replace vinpocetine and the original Huperzia pathway; ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.</p>
83 Budget

Vinpocetine 10 mg

Life Extension
<p>At a lower serving cost than the original, vinpocetine is a defined active compound that does not require a special nutrient salt form. It does not replace ginkgo and the original Huperzia pathway; vinpocetine may lower blood pressure or affect clotting with antihypertensive, anticoagulant, or antiplatelet medicines.</p>
84 Value

Ginkgo Biloba 120 mg

Nature's Bounty
<p>For a more favorable quality-to-cost balance, the extract amount fits common daily use and names the two key ginkgo marker groups. It does not replace vinpocetine and the original Huperzia pathway; missing marker percentages and purity limits reduce confidence despite excellent practical value.</p>
83 Value

Vinpocetine 10 mg

Source Naturals
<p>For a more favorable quality-to-cost balance, vinpocetine is a defined active compound that does not require a special nutrient salt form. It does not replace ginkgo and the original Huperzia pathway; vinpocetine may lower blood pressure or affect clotting with antihypertensive, anticoagulant, or antiplatelet medicines.</p>
81 Value

Extra Strength Ginkgo 120 mg

Doctor's Best
<p>For a more favorable quality-to-cost balance, the key ginkgo marker groups are named, but their percentages and a purity limit are not fully disclosed. It does not replace vinpocetine and the original Huperzia pathway; ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Ginkgo biloba for cognitive impairment and dementia.
    Wieland LS; Ludeman E; Chi Y; Feinberg TM; Chen IH; Chen KH; Zhu Y; Wolverson E; Amri H · The Cochrane database of systematic reviews · 2026
    Meta-analysis10,613 participants82 studies pooledBrain Health forGinkgo
  2. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial.
    van Dongen M; van Rossum E; Kessels A; Sielhorst H; Knipschild P · Journal of clinical epidemiology · 2003
    Randomized trial214 participantsBrain Health forGinkgo
  3. [The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].
    Bagoly E; Fehér G; Szapáry L · Orvosi hetilap · 2007
    Meta-analysisBrain Health forVinpocetine
  4. [Study of the effects of vinpocetin on cognitive functions].
    Valikovics A; Csányi A; Németh L · Ideggyogyaszati szemle · 2012
    Clinical trialBrain Health forVinpocetine
  5. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
    von Gunten A; Schlaefke S; Überla K · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017
    Meta-analysis1,628 participants4 studies pooledCognitive Support Brain Health forGinkgo
  6. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P · Drugs & aging · 2019
    Meta-analysisCognitive Support forGinkgo
  7. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
    Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L · Journal of Alzheimer's disease : JAD · 2015
    Meta-analysis2,561 participants9 studies pooledBrain Health forGinkgo
  8. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
    Riepe M; Hoerr R; Schlaefke S · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025
    Meta-analysis782 participants4 studies pooledBrain Health Productivity Boost forGinkgo
  9. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
    Cui M; You T; Zhao Y; Liu R; Guan Y; Liu J; Liu X; Wang X; Dong Q · Frontiers in pharmacology · 2023
    Randomized trial201 participantsBrain Health Productivity Boost forGinkgo
  10. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
    Herrschaft H; Nacu A; Likhachev S; Sholomov I; Hoerr R; Schlaefke S · Journal of psychiatric research · 2012
    Randomized trial410 participantsBrain Health forGinkgo
  11. Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
    Zhang P; Cao Y; Chen S; Shao L · Pharmacology · 2021
    Randomized trial60 participantsBrain Health forVinpocetine
  12. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.
    Szilágyi G; Nagy Z; Balkay L; Boros I; Emri M; Lehel S; Márián T; Molnár T; Szakáll S; Trón L; Bereczki D; Csiba L; Fekete I; Kerényi L; Galuska L; Varga J; Bönöczk P; Vas A; Gulyás B · Journal of the neurological sciences · 2005
    Randomized trial13 participantsBrain Health forVinpocetine
  13. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.
    Bönöczk P; Gulyás B; Adam-Vizi V; Nemes A; Kárpáti E; Kiss B; Kapás M; Szántay C; Koncz I; Zelles T; Vas A · Brain research bulletin · 2001
    Narrative reviewBrain Health forVinpocetine
  14. Effect of vinpocetine (cognitol™) on cognitive performances of a nigerian population.
    Ogunrin A · Annals of medical and health sciences research · 2014
    Non-randomized trial112 participantsBrain Health Mental Focus forVinpocetine
  15. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
    Tian X; Xu Q; Xia X; Zhang Y; Meng X; Wang A · Journal of neurology · 2024
    Randomized trial3,163 participantsCognitive Support forGinkgo
  16. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF · JAMA · 1997
    Randomized trial309 participantsCognitive Support Productivity Boost forGinkgo
  17. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
    Bachinskaya N; Hoerr R; Ihl R · Neuropsychiatric disease and treatment · 2011
    Randomized trial410 participantsCognitive Support forGinkgo
  18. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O; GOTADAY Study Group · International journal of geriatric psychiatry · 2013
    Randomized trial410 participantsCognitive Support forGinkgo
  19. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
    Hort J; Duning T; Hoerr R · Neuropsychiatric disease and treatment · 2023
    Systematic review946 participants9 studies pooledMental Focus forGinkgo
  20. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2012
    Randomized trial216 participantsMental Focus forGinkgo
  21. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Pharmacopsychiatry · 1996
    Randomized trial216 participantsMental Focus forGinkgo
  22. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.
    Li S; Zhang X; Fang Q; Zhou J; Zhang M; Wang H; Chen Y; Xu B; Wu Y; Qian L; Xu Y · Stroke and vascular neurology · 2021
    Randomized trial348 participantsMental Focus forGinkgo
  23. Ginkgo biloba in the Aging Process: A Narrative Review.
    Barbalho SM; Direito R; Laurindo LF; Marton LT; Guiguer EL; Goulart RA; Tofano RJ; Carvalho ACA; Flato UAP; Capelluppi Tofano VA; Detregiachi CRP; Bueno PCS; Girio RSJ; Araújo AC · Antioxidants (Basel, Switzerland) · 2024
    Narrative review14 studies pooledMental Focus forGinkgo
  24. "Brain-specific" nutrients: a memory cure?
    McDaniel MA; Maier SF; Einstein GO · Nutrition (Burbank, Los Angeles County, Calif.) · 2004
    Narrative reviewMental Focus forVinpocetine
  25. Psychopharmacological effects of vinpocetine in normal healthy volunteers.
    Subhan Z; Hindmarch I · European journal of clinical pharmacology · 1985
    Randomized trial12 participantsMental Focus forVinpocetine
  26. [Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability].
    Kasper S; Schubert H · Fortschritte der Neurologie-Psychiatrie · 2009
    Meta-analysis10 studies pooledProductivity Boost forGinkgo
  27. Dietary Flavonoids and Human Cognition: A Meta-Analysis.
    Cheng N; Bell L; Lamport DJ; Williams CM · Molecular nutrition & food research · 2022
    Meta-analysis5,519 participants80 studies pooledProductivity Boost forGinkgo
  28. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba.
    Elsabagh S; Hartley DE; File SE · Journal of psychopharmacology (Oxford, England) · 2005
    Randomized trial87 participantsProductivity Boost forGinkgo
  29. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial.
    Gavrilova SI; Preuss UW; Wong JW; Hoerr R; Kaschel R; Bachinskaya N; GIMCIPlus Study Group · International journal of geriatric psychiatry · 2015
    Randomized trial160 participantsProductivity Boost forGinkgo
  30. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers.
    Kennedy DO; Jackson PA; Haskell CF; Scholey AB · Human psychopharmacology · 2008
    Randomized trial78 participantsProductivity Boost forGinkgo
  31. Effect of Ginkgo biloba extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial.
    Amiri AA; Jafari R; Amiri AA; Rad HA; Daneshvar F; Charati JY; Amiri AA · Oman journal of ophthalmology · 2025
    Randomized trial144 participantsVision Support forGinkgo
  32. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma.
    Quaranta L; Bettelli S; Uva MG; Semeraro F; Turano R; Gandolfo E · Ophthalmology · 2003
    Randomized trial27 participantsVision Support forGinkgo
  33. [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration].
    Fies P; Dienel A · Wiener medizinische Wochenschrift (1946) · 2002
    Randomized trial99 participantsVision Support forGinkgo
  34. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma.
    Park JW; Kwon HJ; Chung WS; Kim CY; Seong GJ · Korean journal of ophthalmology : KJO · 2012
    Randomized trial30 participantsVision Support forGinkgo
  35. [The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study].
    Lanthony P; Cosson JP · Journal francais d'ophtalmologie · 1989
    Randomized trial29 participantsVision Support forGinkgo
  36. [Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration].
    Avetisov SE; Kiseleva TN; Lagutina IuM; Kravchuk EA · Vestnik oftalmologii · 2007
    Non-randomized trial40 participantsVision Support forVinpocetine